Study of Niacin in Glioblastoma

Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype Clinical Trial

Official title:

A Phase I-II Study of Niacin in Patients With Newly Diagnosed Glioblastoma Receiving Concurrent Radiotherapy and Temozolomide Followed by Monthly Temozolomide

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04677049
• Other study ID #: NiacinCNS2020
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: March 18, 2021
• Est. completion date: January 2026

Study information

• Verified date: October 2023
• Source: AHS Cancer Control Alberta
• Contact: Gloria Roldan Urgoiti, MD
• Phone: 403-521-3688
• Email: Gloria.RoldanUrgoiti[@]ahs.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single institution Phase I-II study to evaluate the tolerability and Maximum Tolerated Dose (MTD) (Phase I) and efficacy (Phase II) of adding Niacin CRT™ to standard first line treatment (concurrent Radiation Therapy (RT) and Temozolomide (TMZ) following by monthly TMZ - AKA Stupp protocol) in patients with newly diagnosed glioblastoma isocitrate dehydrogenase (IDH) wild type.

Description:

During the Phase I stage Niacin CRT™ dose will be escalated every 4 weeks until the maximum tolerated dose (MTD) is determined. The MTD dose will be prescribed to patients during the Phase II stage.

During the Phase I study a sample of blood at baseline, at each level dose of Niacin CRT™, and every two months during the maintenance phase while on Niacin CRTTM will be sent to a lab to evaluate the peripheral activity of Niacin CRT™ in innate immune system cells. These samples will be taken at the time of routine standard of care lab work.

Based on prior clinical trials evaluating niacin extended release formulation for the management of dyslipidaemias there is vast experience on dose escalation of niacin. One of the main side effects is flushing that is ameliorated by escalating doses in intervals no shorter than 4 weeks and usually decreases with time.

Following this schema, there is no increase in dose coinciding with TMZ while administered in a 5/28 days schedule (given daily for 5 days of each 28-day cycle). This will not only improve tolerance but also will allow us to differentiate potential adverse events from chemotherapy from the ones from Niacin CRT™.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 59
• Est. completion date: January 2026
• Est. primary completion date: January 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Adults, 18 years old to 75 years old inclusive.

• New diagnoses of glioblastoma IDH wild type.

• ECOG 0-2 (Appendix I).

• Candidates for concurrent standard first line treatment according to their Neuro-Oncologist and Radiotherapy Oncologist after maximal safe debulking neurosurgery. Patients that only had biopsy are included as long as pathology confirms the diagnoses and it is considered the maximal safe procedure for that patient.

• Adequate hematological, renal and hepatic function (see details in Section 4.1 of the protocol).

• Absence of known human immunodeficiency virus (HIV) infection, chronic hepatitis B or hepatitis C infection.

• Absence of any other serious medical condition according to the medical judgment of the Qualified Investigator prior to registration.

• Absence of any medical condition, which could interfere with oral medication intake.

• Signed informed consent.

• Patients must be accessible for treatment and follow-up. Patients registered on this trial must be treated and followed at the participating centre.

• Women/men of childbearing potential must have agreed to use a highly effective contraceptive method.

Exclusion Criteria:

• Glioblastoma, IDH-mutant.

• Patients with a history of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for = 5 years. Additionally, any low grade or low risk malignancy not requiring treatment will not exclude a patient from participation in the trial.

• Known hypersensitivity to niacin.

• Inability to provide informed consent.

• Active liver disease or unexplained persistent elevations of serum transaminases.

• Active peptic ulcer or active gastrointestinal bleeding.

• Unstable angina or myocardial infarction within 6 months.

• Symptomatic gout.

• Patients on 3-hydroxy-3-methylglutaryl-coenzyme (HMG-COA reductase) inhibitors that cannot discontinue them at least 2 weeks before starting Niacin CRT™.

• Any prior systemic treatment for glioblastoma (standard, evidence based or experimental) or radiotherapy/radiosurgery.

• Individuals with MRI non-compatible metal in the body, or unable to undergo MRI procedures including allergy to gadolinium.

• Patients unfit for any treatment component, including contraindications for radiotherapy or Connective Tissue Disease.

• Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.

• Has known psychiatric or substance abuse disorders that would interfere with compliance with the requirements of the trial.

• Pregnant, breast-feeding, unable and/or unwilling to use contraception methods.

Related Conditions & MeSH terms

• Glioblastoma
• Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Intervention

Drug:
• Niacin CRT
A controlled release technology (CRT) tablet of Niacin

Locations

Country	Name	City	State
Canada	Tom Baker Cancer Centre	Calgary	Alberta

Sponsors (2)

Lead Sponsor	Collaborator
AHS Cancer Control Alberta	Tom Baker Cancer Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determining the Maximum Tolerated Dose	To evaluate and determine maximum tolerated dose (MTD) of Niacin CRT added to concurrent radiotherapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GB).	Up to 24 weeks after registration onto the study
Primary	Evaluating if Niacin CRT Improves Glioblastoma Survival Rates	To evaluate if adding Niacin CRT to current standard first line treatment of GB improves progression free survival (PFS) at 6 months.	6 months after determining the maximum tolerated dose which can last up to 24 weeks after registration onto the study
Secondary	Effect of Niacin CRT in Peripheral Monocytes	To evaluate the effect of Niacin CRT in peripheral monocytes by comparing control monocytoid cells to those that have been treated with Niacin.	From date of registration until the date of first documented disease progression or date of death from any cause, whichever came first, assessed up to 5 years.
Secondary	Response Rate Associated with Niacin	To determine the response rate associated with the investigational regimen.	From date of registration until the date of first documented disease progression or date of death from any cause, whichever came first, assessed up to 5 years.
Secondary	Overall Survival Rate Associated with Niacin	To determine the overall survival (OS) associated with the investigational regimen.	From date of registration until the date of first documented disease progression or date of death from any cause, whichever came first, assessed up to 5 years.
Secondary	Quality of Life While on Study using EORTC QLQ-C30 Questionnaires	To determine Quality of Life (QOL) that will be evaluated throughout the study using EORTC QLQ-C30 questionnaires.	From date of registration until the date of first documented disease progression or date of death from any cause, whichever came first, assessed up to 5 years.
Secondary	Quality of Life While on Study using EORTC BN-20 Questionnaires	To determine Quality of Life (QOL) that will be evaluated throughout the study using EORTC BN-20 questionnaires.	From date of registration until the date of first documented disease progression or date of death from any cause, whichever came first, assessed up to 5 years.